LIVE/VIRTUAL ACTIVITIES

Bio Ascend – Designing CME Solutions For a Virtual World, Our Live and Virtual CME Activities Are Designed to Keep HCPs Educated.

Bio Ascend helps healthcare providers (HCPs) like you stay educated by providing the CME resources you need for continuing education. Our vast selection of activities is devoted entirely to solid tumor and hematologic malignancies – with engaging options in both in-person and virtual environments. Activities feature leading experts discussing the latest data and how to apply it to clinical practice, providing you with critical insight and direction on how to incorporate therapeutic advancements into your practice.

Satellite Symposia:
Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies

August 11, 2021 – Live/Virtual
Time: 1:00 PM – 3:00 PM HST (4 PM PT/6 PM CT/7 PM ET)

There are no fees to register for this symposium

This live symposium on The Treatment of Patients with Hematologic Malignancies will be presented at #PPLC21 and feature expert interpretation of emerging data and guidance regarding current and emerging therapies for the treatment of patients with lymphoma and multiple myeloma.

Be sure to check back in September to view the CME-certified Expert Insights recording with two of the symposium faculty who will provide a summarization of the symposium’s take-home messages most relevant to practice and clinical decision making.

Agenda
7:00PM
Welcome, Introductions, and Pre-session Survey
7:10PM

Overview of CAR T-cell Therapy

  • CAR T-cell mechanism of action
  • Treatment process
7:25PM

Clinical experience with CAR T-cell therapy for lymphoma and myeloma

  • CD19-targeting
  • BCMA-targeting
7:55PM

How to manage novel AE profiles

  • Cytokine release syndrome
  • Neurotoxicity
8:20PM

Practical aspects of CAR T-cell therapy

  • Choosing the right patient for CAR T-cell therapy
  • Optimizing the referral process and multdisciplinary care
8:40PM
Panel Discussion and Audience Q&A
8:50PM
Recap of Key Points and Post-Session Survey
9:00PM
Program Adjourns

Symposium Chair

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris
Professor Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Faculty

Tara Graff, DO, MS
Mission Cancer and Blood
Des Moines, Iowa

Nina Shah, MD

Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Satellite Symposia:
Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies

August 11, 2021 – Live/Virtual
Time: 1:00 PM – 3:00 PM HST (4 PM PT/6 PM CT/7 PM ET)

There are no fees to register for this symposium

This live symposium on The Treatment of Patients with Hematologic Malignancies will be presented at #PPLC21 and feature expert interpretation of emerging data and guidance regarding current and emerging therapies for the treatment of patients with lymphoma and multiple myeloma.

Be sure to check back in September to view the CME-certified Expert Insights recording with two of the symposium faculty who will provide a summarization of the symposium’s take-home messages most relevant to practice and clinical decision making.

Symposium Chair

Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris
Professor Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Faculty

Tara Graff, DO, MS
Mission Cancer and Blood
Des Moines, Iowa

Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Agenda
7:00PM
Welcome, Introductions, and Pre-session Survey
7:10PM

Overview of CAR T-cell Therapy

  • CAR T-cell mechanism of action
  • Treatment process
7:25PM

Clinical experience with CAR T-cell therapy for lymphoma and myeloma

  • CD19-targeting
  • BCMA-targeting
7:55PM

How to manage novel AE profiles

  • Cytokine release syndrome
  • Neurotoxicity
8:20PM

Practical aspects of CAR T-cell therapy

  • Choosing the right patient for CAR T-cell therapy
  • Optimizing the referral process and multdisciplinary care
8:40PM
Panel Discussion and Audience Q&A
8:50PM
Recap of Key Points and Post-Session Survey
9:00PM
Program Adjourns